Forte Biosciences CFO exercises 375 RSUs

Forte Biosciences, Inc. chief financial officer Antony A. Riley exercised restricted stock units that converted into 375 shares of Common Stock on April 1, 2026.

Rhea-AI Filing Summary

Forte Biosciences, Inc. chief financial officer Antony A. Riley exercised restricted stock units that converted into 375 shares of Common Stock on April 1, 2026. These RSUs had a conversion price of $0.00 per share, reflecting equity compensation rather than an open-market purchase.

To cover tax obligations from the vesting, 134 Common Shares were withheld at $24.86 per share, which is treated as a tax-withholding disposition rather than a traditional stock sale. After these transactions, Riley directly held 41,982 Common Shares and 1,125 RSUs, representing ongoing equity exposure to the company.

Insider Trade Summary

375 shares exercised/converted

Exercise 3 txns

Insider Riley Antony A

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	375	$0.00	$0.00
Exercise	Common Stock	375	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	134	$24.86	$3K

Holdings After Transaction: Restricted Stock Units — 1,125 contracts (Direct); Common Stock — 41,982 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
2. F2. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.

Key Figures

RSUs exercised: 375 units Tax-withheld shares: 134 shares Post-transaction Common Stock: 41,982 shares +3 more

6 metrics

RSUs exercised 375 units Converted into 375 shares of Common Stock on April 1, 2026

Tax-withheld shares 134 shares Common Stock withheld at $24.86 per share for taxes

Post-transaction Common Stock 41,982 shares Directly held by CFO after April 1, 2026 transactions

Remaining RSUs 1,125 units Restricted Stock Units held after the reported exercise

RSU conversion price $0.00 per share Exercise or conversion price for RSUs into Common Stock

Tax withholding price $24.86 per share Price applied to 134 withheld shares of Common Stock

Key Terms

Restricted Stock Units, Quarterly Vesting Date, Service Provider, 2021 Equity Incentive Plan, +1 more

5 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Quarterly Vesting Date financial

"one-sixteenth (1/16th) of the RSUs shall vest on each Quarterly Vesting Date"

Service Provider financial

"Subject to the Reporting Person continuing to be a Service Provider through each vesting date"

2021 Equity Incentive Plan financial

"Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date"

tax-withholding disposition financial

"Payment of exercise price or tax liability by delivering securities"

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

FAQ

What insider transaction did Forte Biosciences (FBRX) report for its CFO?

Forte Biosciences reported that CFO Antony A. Riley exercised restricted stock units into 375 shares of Common Stock. The RSUs converted at $0.00 per share as part of his equity compensation, rather than through an open-market stock purchase.

How many Forte Biosciences (FBRX) shares were withheld for taxes in this Form 4?

The filing shows 134 shares of Forte Biosciences Common Stock were withheld at $24.86 per share. This F-coded transaction covers tax obligations from the RSU vesting and is not considered an open-market sale by the CFO.

How many Forte Biosciences (FBRX) shares does the CFO hold after this transaction?

After the reported transactions, CFO Antony A. Riley directly holds 41,982 shares of Forte Biosciences Common Stock. He also has 1,125 restricted stock units outstanding, providing additional potential future equity if vesting conditions continue to be met.

What are restricted stock units (RSUs) in the Forte Biosciences (FBRX) filing?

The filing explains each restricted stock unit represents a contingent right to receive one share of Forte Biosciences Common Stock. These RSUs vest over time, subject to the CFO continuing as a service provider under the company’s 2021 Equity Incentive Plan.

How do Forte Biosciences (FBRX) RSUs vest for the CFO?

According to the disclosure, one-sixteenth of the CFO’s RSUs vest on each Quarterly Vesting Date, beginning on or after February 1, 2023. Quarterly Vesting Dates are defined as January 1, April 1, July 1, and October 1 in each calendar year.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/03/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Riley Antony A

(Last) (First) (Middle)

C/O FORTE BIOSCIENCES, INC.

3060 PEGASUS PARK DR., BLDG 6

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Forte Biosciences, Inc. [ FBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		M		375	A	(1)	42,116	D
Common Stock	04/01/2026		F		134	D	$24.86	41,982	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	04/01/2026		M			375	(2)	(2)	Common Stock	375	$0	1,125	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.

2. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.

	/s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)